We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Amisha Wallia

Amisha Wallia MD

Assistant Professor of Endocrinology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Dr. Wallia is an endocrinologist and clinical instructor at Northwestern University Feinberg School of Medicine and also holds a secondary appointment at the Center for Health Care Studies, Institute of Public Health and Medicine. She completed her medical training at Georgetown University School of Medicine and completed her internal medicine and endocrinology training at Northwestern University.  She completed a Masters of Clinical Investigation during her training and completed an additional post-doctoral year examining the effects of hyperglycemia on post-transplant outcomes. Her current research includes a randomized controlled trial evaluating the effects of intensive and moderate glycemic control on outcomes following liver transplantation. In addition she has more recently been studying the use of engineering and safety methods to improve identification and treatment of hyperglycemia in the post-transplant population. Dr. Wallia has also been integral in efforts at her institution to improve diabetes transitions of care and decrease recurrent admissions for patients with diabetic ketoacidosis, and is involved in medication safety and quality improvement initiatives within Northwestern Memorial Hospital. Long terms she hopes to build novel integrated diabetes care management programs for those patients who are at highest risk for poor outcomes due to co-morbid conditions (such as post-transplant or those with recurrent diabetic ketoacidosis).